Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Tango Therapeutics (TNGX) Net Cash Flow (2020 - 2025)

Historic Net Cash Flow for Tango Therapeutics (TNGX) over the last 6 years, with Q3 2025 value amounting to $19.1 million.

  • Tango Therapeutics' Net Cash Flow rose 110518.33% to $19.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $5.2 million, marking a year-over-year increase of 18315.98%. This contributed to the annual value of $2.3 million for FY2024, which is 6087.18% down from last year.
  • Latest data reveals that Tango Therapeutics reported Net Cash Flow of $19.1 million as of Q3 2025, which was up 110518.33% from -$19.2 million recorded in Q2 2025.
  • Tango Therapeutics' 5-year Net Cash Flow high stood at $154.1 million for Q3 2021, and its period low was -$62.2 million during Q4 2021.
  • For the 5-year period, Tango Therapeutics' Net Cash Flow averaged around $1.6 million, with its median value being -$4.3 million (2022).
  • Over the last 5 years, Tango Therapeutics' Net Cash Flow had its largest YoY gain of 982586.78% in 2021, and its largest YoY loss of 5967268.04% in 2021.
  • Tango Therapeutics' Net Cash Flow (Quarter) stood at -$62.2 million in 2021, then skyrocketed by 35.17% to -$40.3 million in 2022, then soared by 119.46% to $7.9 million in 2023, then soared by 108.63% to $16.4 million in 2024, then increased by 16.38% to $19.1 million in 2025.
  • Its Net Cash Flow was $19.1 million in Q3 2025, compared to -$19.2 million in Q2 2025 and -$11.1 million in Q1 2025.